UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 212

Sortiert nach

Ixazomib-induced Sweet’s syndrome

International journal of hematology, 2020-02, Vol.111 (2), p.161-162

2020

Volltextzugriff (PDF)

Pomalidomide‐bortezomib‐dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM

Cancer science, 2020-06, Vol.111 (6), p.2116-2122

2020

Volltextzugriff (PDF)

Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy

Japanese journal of clinical oncology, 2022-01, Vol.52 (1), p.29-38

2022

Volltextzugriff (PDF)

Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma

International journal of hematology, 2018-04, Vol.107 (4), p.460-467

2018

Volltextzugriff (PDF)

Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard‐dose azacitidine

Cancer reports, 2024-01, Vol.7 (1), p.e1938-n/a

2024

Volltextzugriff (PDF)

Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia

International journal of hematology, 2014-01, Vol.99 (1), p.41-52

2014

Volltextzugriff (PDF)

Lenalidomide and low‐dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study

Cancer science, 2016-05, Vol.107 (5), p.653-658

2016

Volltextzugriff (PDF)

Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic‐phase chronic myeloid leukemia based on early achievement of deep molecular response (MR4.5): The phase 2, multicenter N‐Road study

Cancer medicine (Malden, MA), 2020-06, Vol.9 (11), p.3742-3751

2020

Volltextzugriff (PDF)

Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response

NPJ systems biology and applications, 2022-10, Vol.8 (1), p.39-39, Article 39

2022

Volltextzugriff (PDF)

Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia

International journal of hematology, 2011-05, Vol.93 (5), p.618-623

2011

Volltextzugriff (PDF)

Quantification of mRNA in Whole Blood by Assessing Recovery of RNA and Efficiency of cDNA Synthesis

Clinical chemistry (Baltimore, Md.), 2006-04, Vol.52 (4), p.634-642

2006

Volltextzugriff (PDF)

Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations

Clinical cancer research, 2022-07, Vol.28 (13), p.2753-2761

2022

Volltextzugriff (PDF)

Efficacy of Molecular Response at 1 or 3 Months after the Initiation of Dasatinib Treatment Can Predict an Improved Response to Dasatinib in Imatinib-Resistant or Imatinib-Intolerant Japanese Patients with Chronic Myelogenous Leukemia during the Chronic Phase

Journal of Clinical and Experimental Hematopathology, 2014, Vol.54(3), pp.197-204

2014

Volltextzugriff (PDF)

ALK+, CD30−, CD20− Large B-Cell Lymphoma Containing Anaplastic Lymphoma Kinase (ALK) Fused to Clathrin Heavy Chain Gene (CLTC)

Modern pathology, 2003-08, Vol.16 (8), p.828-832

2003

Volltextzugriff (PDF)

Durable Leukemic Remission and Autologous Marrow Recovery with Random Chromosomal Abnormalities after Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia

Case reports in hematology, 2019-01, Vol.2019, p.9710790-5

2019

Volltextzugriff (PDF)

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

The New England journal of medicine, 2016-10, Vol.375 (14), p.1319-1331

2016

Volltextzugriff (PDF)

Compression therapy using surgical gloves is ineffective for the prevention of vincristine-induced neuropathy in patients with malignant lymphoma

Supportive care in cancer, 2024-03, Vol.32 (3), p.173-173, Article 173

2024

Volltextzugriff (PDF)

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

The lancet oncology, 2019-06, Vol.20 (6), p.781-794

2019

Volltextzugriff (PDF)

Ex Vivo Induction of mRNA in Human Whole Blood as a New Platform of Drug and Dietary Supplement Development

Pharmaceutical research, 2008-05, Vol.25 (5), p.1116-1124

2008

Volltextzugriff (PDF)

Efficacy of Molecular Response at 1 or 3 Months after the Initiation of Dasatinib Treatment Can Predict an Improved Response to Dasatinib in Imatinib-Resistant or Imatinib- Intolerant Japanese Patients with Chronic Myelogenous Leukemia during the Chronic Phase

Journal of Clinical and Experimental Hematopathology, 2014-12, Vol.54 (3), p.197-204

2014

Volltextzugriff (PDF)

Dasatinib Is an Effective Treatment for Angioimmunoblastic T-cell Lymphoma

Cancer research (Chicago, Ill.), 2020-05, Vol.80 (9), p.1875-1884

2020

Volltextzugriff (PDF)

FIP1L1::PDGFRA-positive chronic eosinophilic leukemia showing slowly progressive cardiac impairment

Rinshō ketsueki, 2022, Vol.63 (12), p.1648

2022

Volltextzugriff (PDF)

Follicular lymphoma with secondary central nervous system relapse: a case report and literature review

Oxford Medical Case Reports, 2023-11, Vol.2023 (11), p.403

2023

Volltextzugriff (PDF)

Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan

Japanese journal of clinical oncology, 2023-06, Vol.53 (7), p.595-603

2023

Volltextzugriff (PDF)

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 Mutations

Blood, 2020-11, Vol.136 (Supplement 1), p.5-7

2020

Volltextzugriff (PDF)

1 – 25 von 212

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(155)
Mit Volltextzugriff
(192)

Publikationsform

Sprache

Englisch
(177)
Japanisch
(72)

Erscheinungsjahr

n.n

Thema

Science & Technology
(101)
Life Sciences & Biomedicine
(89)
Humans
(81)
Male
(38)
Female
(37)
Middle Aged
(31)
Biological And Medical Sciences
(30)
Aged
(29)
Adult
(28)
Oncology
(28)
Hematology
(23)
Medical Sciences
(22)
Aids/hiv
(18)
Multiple Myeloma
(18)
Animals
(15)
Fundamental And Applied Biological Sciences. Psychology
(14)
Hiv-1 - Immunology
(14)
Virology
(13)
Aged, 80 And Over
(11)
Human Immunodeficiency Virus 1
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Ixazomib-induced Sweet’s syndrome

Pomalidomide‐bortezomib‐dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM

Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy

Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma

Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard‐dose azacitidine

Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia

Lenalidomide and low‐dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study

Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic‐phase chronic myeloid leukemia based on early achievement of deep molecular response (MR4.5): The phase 2, multicenter N‐Road study

Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response

Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia

Quantification of mRNA in Whole Blood by Assessing Recovery of RNA and Efficiency of cDNA Synthesis

Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations

Efficacy of Molecular Response at 1 or 3 Months after the Initiation of Dasatinib Treatment Can Predict an Improved Response to Dasatinib in Imatinib-Resistant or Imatinib-Intolerant Japanese Patients with Chronic Myelogenous Leukemia during the Chronic Phase

ALK+, CD30−, CD20− Large B-Cell Lymphoma Containing Anaplastic Lymphoma Kinase (ALK) Fused to Clathrin Heavy Chain Gene (CLTC)

Durable Leukemic Remission and Autologous Marrow Recovery with Random Chromosomal Abnormalities after Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Compression therapy using surgical gloves is ineffective for the prevention of vincristine-induced neuropathy in patients with malignant lymphoma

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Ex Vivo Induction of mRNA in Human Whole Blood as a New Platform of Drug and Dietary Supplement Development

Efficacy of Molecular Response at 1 or 3 Months after the Initiation of Dasatinib Treatment Can Predict an Improved Response to Dasatinib in Imatinib-Resistant or Imatinib- Intolerant Japanese Patients with Chronic Myelogenous Leukemia during the Chronic Phase

Dasatinib Is an Effective Treatment for Angioimmunoblastic T-cell Lymphoma

FIP1L1::PDGFRA-positive chronic eosinophilic leukemia showing slowly progressive cardiac impairment

Follicular lymphoma with secondary central nervous system relapse: a case report and literature review

Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan

Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 Mutations

Suchergebnisse filtern